Medications for Advanced Breast Cancer

3 results

  • aromasin

    (exemestane)
    Pharmacia & Upjohn Company LLC
    AROMASIN is indicated for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer after two to three years of tamoxifen, completing a total of five years of therapy. It is also used to treat advanced breast cancer in postmenopausal women progressing after tamoxifen.

  • kisqali

    (ribociclib)
    Novartis Pharmaceuticals Corporation
    KISQALI is indicated for the adjuvant treatment of adults with HR-positive, HER2-negative early breast cancer at high risk of recurrence, and for advanced or metastatic HR-positive, HER2-negative breast cancer in combination with aromatase inhibitors or fulvestrant.

  • verzenio

    (abemaciclib)
    Eli Lilly and Company
    VERZENIO (abemaciclib) is indicated for adults with HR-positive, HER2-negative breast cancer. It is used in combination with endocrine therapy for early breast cancer at high risk of recurrence and for advanced or metastatic cases, either with an aromatase inhibitor, fulvestrant, or as monotherapy after prior treatments.